AS/Spondyloarthritis
Chronic low back pain is a common complaint that brings patients to the doctor’s attention. Although the majority of low back pain is mechanical in nature, an important minority is inflammatory in nature. Therefore, prompt referral to a rheumatologist is warranted particularly in the presence of other features suggestive of axial spondyloarthritis (axSpA).
Dr. John Cush RheumNow
1 year 7 months ago
Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA
Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI
Dr. John Cush RheumNow
1 year 7 months ago
RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? CLICK here to answer: https://t.co/afJmqzzPYi
Mithu Maheswaranathan, MD
1 year 7 months ago
Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
Robert B Chao, MD
1 year 7 months ago
Anterior uveitis incidence across different axSpA treatments
Large review and meta-analysis on TNFi, IL-17i, JAKi
Immunomodulatory therapy protective against uveitis flare
Greatest in TNFi and JAKi
@RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt
Nouf Al hemmadi
1 year 7 months ago
Dr. @drpnash @RheumNow
➡️Difficult to treat Axial SpA ;
23,0000 🧍♀️🧍:
1-Failure of 3 biolo - targ synth, or different mechanism of action.
2- Around 10% of patients.
1-Female.
2-Peripheral arthritis.
3-Psoriasis
4-Lipid , HTN, Smoking.
https://t.co/B99TcXjjiF…
#ACR23
Eric Dein
1 year 7 months ago
A#2545 IV SEC for SpA #ACR23 @Rheumow
Approved by FDA, though diff dose
Who: Medicare/cost/QoL benefit for IV or obese (wt based dose)
W16: 41% ASAS40 v 23% PBO
W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%)
SAE 6%, discontinuation 3.5%
#ACRBest https://t.co/ruW0ys49gk
Eric Dein
1 year 7 months ago
A#2546 Anti-IFX Ab in AS
#ACR23 @RheumNow
Anti-IFX in 45% in f/u, 85% in 1st yr
MTX decr anti-IFX (18 v 42%)
Anti-IFX - higher inflamm markers, infus rxn, lower serum levels and Rx fail
Pt w/o anti-IFX Ab more likely to tolerate tapering https://t.co/eN9SqGyGgm
Eric Dein
1 year 7 months ago
A#2547 #ACR23 @RheumNow
Diff 2 Treat (D2T) AxSpa
D2T: fail 2+ b/tsDMARDs w 2 MoA
Very D2T: failure of Rx in less than 2 yrs
28% D2T, 3.8% Very D2T (Compare to 7-10% D2TRA)
More likely: peripheral, uveitis, higher BASDAI, FM
Very D2T also w IBD, higher CRP, longer dis duration https://t.co/HcIXnDRrIq
Poster Hall